Literature DB >> 28062192

Direct effects of glucose, insulin, GLP-1, and GIP on bulbospinal neurons in the rostral ventrolateral medulla in neonatal wistar rats.

Naoki Oshima1, Hiroshi Onimaru2, Hidehito Matsubara3, Takahiro Uchida3, Atsushi Watanabe3, Toshihiko Imakiire3, Yasuhiro Nishida4, Hiroo Kumagai3.   

Abstract

Although patients with diabetes mellitus (DM) often exhibit hypertension, the mechanisms responsible for this correlation are not well known. We hypothesized that the bulbospinal neurons in the rostral ventrolateral medulla (RVLM) are affected by the levels of glucose, insulin, or incretins (glucagon like peptide-1 [GLP-1] or glucose-dependent insulinotropic peptide [GIP]) in patients with DM. To investigate whether RVLM neurons are activated by glucose, insulin, GLP-1, or GIP, we examined changes in the membrane potentials of bulbospinal RVLM neurons using whole-cell patch-clamp technique during superfusion with various levels of glucose or these hormones in neonatal Wistar rats. A brainstem-spinal cord preparation was used for the experiments. A low level of glucose stimulated bulbospinal RVLM neurons. During insulin superfusion, almost all the RVLM neurons were depolarized, while during GLP-1 or GIP superfusion, almost all the RVLM neurons were hyperpolarized. Next, histological examinations were performed to examine transporters for glucose and receptors for insulin, GLP-1, and GIP on RVLM neurons. Low-level glucose-depolarized RVLM neurons exhibited the presence of glucose transporter 3 (GLUT3). Meanwhile, insulin-depolarized, GLP-1-hyperpolarized, and GIP-hyperpolarized RVLM neurons showed each of the respective specific receptor. These results indicate that a low level of glucose stimulates bulbospinal RVLM neurons via specific transporters on these neurons, inducing hypertension. Furthermore, an increase in insulin or a reduction in incretins may also activate the sympathetic nervous system and induce hypertension by activating RVLM neurons via their own receptors.
Copyright © 2016 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  GIP; GLP-1; RVLM neurons; glucose; hypertension; insulin

Mesh:

Substances:

Year:  2017        PMID: 28062192     DOI: 10.1016/j.neuroscience.2016.12.039

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  5 in total

1.  Restoration of Rostral Ventrolateral Medulla Cystathionine-γ Lyase Activity Underlies Moxonidine-Evoked Neuroprotection and Sympathoinhibition in Diabetic Rats.

Authors:  Mohamed A Fouda; Shaimaa S El-Sayed; Abdel A Abdel-Rahman
Journal:  J Pharmacol Exp Ther       Date:  2017-11-13       Impact factor: 4.030

Review 2.  Central Mechanisms of Glucose Sensing and Counterregulation in Defense of Hypoglycemia.

Authors:  Sarah Stanley; Amir Moheet; Elizabeth R Seaquist
Journal:  Endocr Rev       Date:  2019-06-01       Impact factor: 19.871

3.  Exenatide reduces oxidative stress and cell death in testis in iron overload rat model.

Authors:  Suleyman Yesil; Nuran Sungu; Aydan Kilicarslan; Serife Mehlika Kuskonmaz; Halil Kara; Aysegul Kucuk; Fazli Polat; Mustafa Kavutcu; Mustafa Arslan
Journal:  Exp Ther Med       Date:  2018-09-26       Impact factor: 2.447

4.  Erythropoietin, a putative neurotransmitter during hypoxia, is produced in RVLM neurons and activates them in neonatal Wistar rats.

Authors:  Naoki Oshima; Hiroshi Onimaru; Akira Yamagata; Seigo Itoh; Hidehito Matsubara; Toshihiko Imakiire; Yasuhiro Nishida; Hiroo Kumagai
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-02-14       Impact factor: 3.619

5.  Central Glucagon-like Peptide-1 Receptor Signaling via Brainstem Catecholamine Neurons Counteracts Hypertension in Spontaneously Hypertensive Rats.

Authors:  Kenichi Katsurada; Masanori Nakata; Toshinobu Saito; Boyang Zhang; Yuko Maejima; Shyam S Nandi; Neeru M Sharma; Kaushik P Patel; Kazuomi Kario; Toshihiko Yada
Journal:  Sci Rep       Date:  2019-09-19       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.